Digestive Diseases and Sciences

, Volume 53, Issue 2, pp 385–393

Long-Term Proton Pump Inhibitor Use in Children: A Retrospective Review of Safety

Original Paper


The objective of this work was to assess the efficacy of continuous proton pump inhibitor (PPI) therapy in children and to evaluate changes in biochemical, endoscopic, and histologic parameters during such treatment. A retrospective review of children receiving PPI therapy continuously for 1 year or more with baseline and follow-up esophageal and gastric biopsies on treatment was conducted to assess type, frequency, and duration of PPI dosing, symptom relief, gastrin levels, histologic findings, and adverse events. A total of 113 children (59 male, median age 4.5 years) were identified. Of these, 31% (35/113) were neurologically impaired. The median treatment duration was 35.2 months. Elevated serum gastrin levels occurred in 73% of children with no statistically significant differences in gastrin level by PPI type, dose, and dosing frequency or treatment duration. Adverse events were reported by 12% of children: diarrhea (5%) and constipation (4%) were the most frequent. Long-term PPI therapy appears to be effective, safe and well tolerated in children despite some biochemical, endoscopic, and histologic changes.


Proton pump inhibitors Children Gastrin Gastritis Safety Long-term use 


  1. 1.
    Nelson SP, Chen EH, Syniar GM, Christoffel KK (1997) Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 151:569–572PubMedGoogle Scholar
  2. 2.
    Nelson SP, Chen EH, Syniar GM, Christoffel KK (1998) One-year follow-up of symptoms of gastroesophageal reflux during infancy. Pediatrics 102(6):E67. http://www.pediatrics.org/cgi/content/full/102/6/c67 Google Scholar
  3. 3.
    Nelson SP, Chen EH, Syniar GM, Christoffel KK, for the Pediatric Practice Research Group (2000) Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Arch Pediatr Adolesc Med 54:150–154Google Scholar
  4. 4.
    Ramesh P, Santiago M, Schmidt K, Gunasekaran TS (2001) Prevalence of gastroesophageal reflux disease symptoms in an African American predominant adolescent high school population. J Pediatr Gastroenterol Nutr 33:A194Google Scholar
  5. 5.
    Ramesh P, Braden D, Dey S, Gunasekaran TS (2002) Prevalence of gastroesophageal reflux disease (GERD) symptoms in a Caucasian predominant adolescent population. Gastroenterology 122:A213Google Scholar
  6. 6.
    Waring JP, Feiler MJ, Hunter JG, Smith CD, Gold BD (2002) Childhood gastroesophageal reflux symptoms in adult patients. J Pediatr Gastroenterol Nutr 35:334–338PubMedCrossRefGoogle Scholar
  7. 7.
    El-Serag HB, Gilger M, Carter J, Genta RM, Rabeneck L (2004) Childhood GERD is a risk factor for GERD in adolescents and young adults. Am J Gastroenterol 100:806–812CrossRefGoogle Scholar
  8. 8.
    DiBaise J, Young R, Ward B, Lyden E, Vanderhoof J (2005) A retrospective, case-control study of the natural history of pediatric GERD. Gastroenterology (4 Suppl 2):Abstract M1070Google Scholar
  9. 9.
    Hirschowitz BI, Simmons J, Mohnen J (2005) Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol 3(1):39–48PubMedCrossRefGoogle Scholar
  10. 10.
    Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L (2002) Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 35:S308–S318PubMedGoogle Scholar
  11. 11.
    Hassall E, Israel D, Shepherd R, Radke M, Dalvag A, Skold B, Junghard O, Lundborg P (2000) Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr 137:800–807PubMedCrossRefGoogle Scholar
  12. 12.
    Huang J-Q, Hunt RH (1998) Meta-analysis of comparative trials for healing erosive esophagitis with proton pump inhibitors and H2-receptor antagonists. Gastroenterology 114:A154CrossRefGoogle Scholar
  13. 13.
    Gunasekaran T, Gupta S, Gremse D, Karol M, Pan WJ, Chiu YL, Keith R, Fitzgerald J (2002) Lansoprazole in adolescents with gastroesophageal reflux disease. Pharmacokinetics, pharmcodynamics, symptom relief efficacy and tolerability. J Pediatr Gastroenterol Nutr 35(Suppl 4):S327–S335PubMedGoogle Scholar
  14. 14.
    Fiedorek S, Tolia V, Gold BD, Huang B, Stolle J, Lee C, Gremse D (2005) Efficacy and safety of lansoprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 40(3):319–327PubMedCrossRefGoogle Scholar
  15. 15.
    Metz DC (2004) Managing gastroesophageal reflux disease for the lifetime of the patient: evaluating the long-term options. Am J Med 117(5A):49S–55SPubMedGoogle Scholar
  16. 16.
    Onimoe GI, Tolia V, Thomas R (2005) Clinical presentation and long term outcome of gastroesophageal reflux disease in children and adolescents. J Pediatr Gastroenterol Nutr 41(4):A34Google Scholar
  17. 17.
    Wang K, Lin HJ, Perng CL, Tseng GY, Yu KW, Chang FY, Lee SD (2004) The effect of H2-receptor antagonist and proton pump inhibitor on microbial proliferation in the stomach. Hepatogastroenterology 51(59):1540–1543PubMedGoogle Scholar
  18. 18.
    Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB (2004) Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292(16):1955–1960PubMedCrossRefGoogle Scholar
  19. 19.
    Canani RB, Cirillo P, Roggero P et al. (2006) Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 117(5):e817–e820PubMedCrossRefGoogle Scholar
  20. 20.
    Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, Lloyd D, Havu N, Frame MH, Roman J, Walan A (2000) Long-term study group long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 118:661–669PubMedCrossRefGoogle Scholar
  21. 21.
    Israel DM, Hassall E (1998) Omeprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. J Pediatr Gastroenterol Nutr 27:568–579PubMedCrossRefGoogle Scholar
  22. 22.
    Andersson T, Hassall E, Lundborg P, Shepherd R, Radke M, Marcon M, Dalvag A, Martin S, Behrens R, Koletzko S, Becker M, Drouin E, Gothberg G (2000) Pharmacokinetics of orally administered omeprazole in children: International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol 95:3101–3106PubMedCrossRefGoogle Scholar
  23. 23.
    Hassall E, El-Serag H, Kerr W (2005) Continuous use of proton pump inhibitors in children up to 11 yrs duration. Gastroenterology (4 Suppl 2): Abstract T1669Google Scholar
  24. 24.
    SAS Institute (2001) SAS 8.2. SAS Institute, CaryGoogle Scholar
  25. 25.
    Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, Mitchell B, Beveridge BR, Laurence BH, Gibson GG (1988) Healing and relapse of severe peptic oesophagitis after treatment with omeprazole. Gastroenterology 95(4):903–912PubMedGoogle Scholar
  26. 26.
    Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. Am J Surg Pathol 20:1161–1181PubMedCrossRefGoogle Scholar
  27. 27.
    Marchetti F, Gerarduzzi T, Ventura A (2003) Proton pump inhibitors in children: a review. Dig Liver Dis 35:738–746PubMedCrossRefGoogle Scholar
  28. 28.
    Bohmer CJ, Niezen-de Boer RC, Klinkenberg-Knol EC, Meuwissen SG (1998) Omeprazole: therapy of choice in intellectually disabled children. Arch Pediatr Adolesc Med 152(11):1113–1118PubMedGoogle Scholar
  29. 29.
    DeVault KR, Castell DO (2005) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100(1):190–200PubMedCrossRefGoogle Scholar
  30. 30.
    Pounder R, Smith J (1990) Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am 19:141–153PubMedGoogle Scholar
  31. 31.
    Mattsson H, Havu N, Brautigam J, Carlsson K, Lundell L, Carlsson E (1991) Parietal gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffin-like cell carcinoids in the rat. Gastroenterology 100:311–319PubMedGoogle Scholar
  32. 32.
    Freston JW, Borch K, Brand SJ, Carlsson E, Creutzfeldt W, Hakanson R, Olbe L, Solcia E, Walsh JH, Wolfe MM (1995) Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis. Dig Dis Sci 40(2 Suppl):50S–62SPubMedCrossRefGoogle Scholar
  33. 33.
    Pashankar DS, Israel DM, Jevon GP, Buchan AM (2001) Effect of long-term omeprazole treatment on antral G and D cells in children. J Pediatr Gastroenterol Nutr 33(5):537–542PubMedCrossRefGoogle Scholar
  34. 34.
    Singh P, Indaram A, Greenberg R, Visvalingam V, Bank S (2000) Long term omeprazole therapy for reflux esophagitis: follow-up in serum gastrin levels, EC cell hyperplasia and neoplasia. World J Gastrenterol 6:789–792Google Scholar
  35. 35.
    Hage E, Hendel L, Gustafsen J, Hendel J (2003) Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole. Eur J Gastroenterol Hepatol 15(7):781–789PubMedCrossRefGoogle Scholar
  36. 36.
    Laine L, Ahnen D, McClain C, Solcia E, Walsh JH (2000) Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 14(6):651–668PubMedCrossRefGoogle Scholar
  37. 37.
    Pashankar DS, Israel DM (2002) Gastric polyps and nodules in children receiving long-term omeprazole therapy. J Pediatr Gastroenterol Nutr 35(5):658–662PubMedCrossRefGoogle Scholar
  38. 38.
    Graffner H, Singh G, Chaudry I, Milsom JW (1992) Omeprazole-induced hypergastrimenia does no influence growth of colon carcinoma. Dig Dis Sci 37(4):485–489PubMedCrossRefGoogle Scholar
  39. 39.
    Pinson DM, Havu N, Sztern MI, Mattsson H, Looney GA, Kimler BF, Hurwitz A (1995) Drug-induced hypergastrinemia: absence of trophic effects on colonic carcinoma in rats. Gastroenterology 108(4):1068–1074PubMedCrossRefGoogle Scholar
  40. 40.
    Litalien C, Theoret Y, Faure C (2005) Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 44(5):441–466PubMedCrossRefGoogle Scholar
  41. 41.
    de Korwin JD, Ducrotte P, Vallot T (2004) New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases? Presse Med 33(11):746–754PubMedCrossRefGoogle Scholar
  42. 42.
    Robinson M, Horn J (2003) Clinical pharmacology of proton pump inhibitors: what the practicing physician needs to know. Drugs 63(24):2739–2754PubMedCrossRefGoogle Scholar
  43. 43.
    Ruscin JM, Page RL, Valuck RJ (2002) Vitamin B (12) deficiency associated with histamine (2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 36(5):812–816PubMedCrossRefGoogle Scholar
  44. 44.
    Valuck RJ, Ruscin JM (2004) A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 57(4):422–428PubMedCrossRefGoogle Scholar
  45. 45.
    Howden CW (2000) Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 30(1):29–33PubMedCrossRefGoogle Scholar
  46. 46.
    Force RW, Meeker AD, Cady PS, Culbertson VL, Force WS, Kelley CM (2003) Ambulatory care increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 37(4):490–493PubMedCrossRefGoogle Scholar
  47. 47.
    ter Heide H, Hendriks HJ, Heijmans H, Menheere PP, Spaapen LJ, Bakker JA, Forget PP (2001) Are children with cystic fibrosis who are treated with a proton-pump inhibitor at risk for vitamin B(12) deficiency? J Pediatr Gastroenterol Nutr 33(3):342–345PubMedCrossRefGoogle Scholar
  48. 48.
    Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24):2947–2953PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Division of GastroenterologyChildren’s Hospital of MichiganDetroitUSA
  2. 2.Farmington HillsUSA

Personalised recommendations